Overview

* Knight Therapeutics ( KHTRF ) Q3 revenue grows 32% yr/yr, beating analyst expectations

* Adjusted EBITDA for Q3 rises 56%, reflecting strong operational performance

* Company launched NCIB to purchase up to 3 mln shares over 12 months

Outlook

* Knight raises 2025 revenue guidance to C$430 mln - C$440 mln

* Company expects adjusted EBITDA to be 13.5% - 14.5% of revenues

* Outlook driven by performance of promoted products

Result Drivers

* REVENUE GROWTH - Revenue increased 32% yr/yr driven by Paladin and Sumitomo transactions and key promoted products

* GROSS MARGIN IMPACT - Gross margin affected by hyperinflation and Paladin transaction expenses

* PRODUCT LAUNCHES - New product launches and expanded distribution agreements to drive future growth

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat C$121.55 C$107

Revenue mln mln (6

Analysts

)

Q3 Net -C$3.79

Income mln

Q3 C$55.16

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for Knight Therapeutics Inc ( KHTRF ) is C$7.50, about 22.1% above its November 5 closing price of C$5.84

* The stock recently traded at 410 times the next 12-month earnings vs. a P/E of 71 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)